Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Sznol

Showing results (71-80 of 188) with videos related to

Pageof 19
Sort By:
Journal for Immunotherapy of Cancer|March 27, 2020
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanomaNicholas D Klemen, Melinda Wang, Jill C Rubinstein, et al.
Plos One|July 11, 2013
A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human CancerRossitza Lazova, Greggory S Laberge, Eric Duvall, et al.
Current Problems in Cancer|September 14, 2011
Melanoma brain metastases: is it time to reassess the bias?Jaclyn C Flanigan, Lucia B Jilaveanu, Mark Faries, et al.
Ophthalmology|February 9, 2019
Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case SeriesJenna May Kim, Miguel A Materin, Mario Sznol, et al.
Journal for Immunotherapy of Cancer|March 4, 2021
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCCPetra Ross-Macdonald, Alice M Walsh, Scott D Chasalow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
C-Raf is associated with disease progression and cell proliferation in a subset of melanomasLucia B Jilaveanu, Christopher R Zito, Saadia A Aziz, et al.
Journal for Immunotherapy of Cancer|March 24, 2017
Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanomaJames W Smithy, Lauren M Moore, Vasiliki Pelekanou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic SitesHarriet M Kluger, Christopher R Zito, Meaghan L Barr, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid TumorsChristian U Blank, Deborah J Wong, Thai H Ho, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2014
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivoRituparna Das, Rakesh Verma, Mario Sznol, et al.
Pageof 19

Showing results (71-80 of 188) with videos related to

Sort By:
Pageof 19
Journal for Immunotherapy of Cancer|March 27, 2020
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanomaNicholas D Klemen, Melinda Wang, Jill C Rubinstein, et al.
Plos One|July 11, 2013
A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human CancerRossitza Lazova, Greggory S Laberge, Eric Duvall, et al.
Current Problems in Cancer|September 14, 2011
Melanoma brain metastases: is it time to reassess the bias?Jaclyn C Flanigan, Lucia B Jilaveanu, Mark Faries, et al.
Ophthalmology|February 9, 2019
Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case SeriesJenna May Kim, Miguel A Materin, Mario Sznol, et al.
Journal for Immunotherapy of Cancer|March 4, 2021
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCCPetra Ross-Macdonald, Alice M Walsh, Scott D Chasalow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
C-Raf is associated with disease progression and cell proliferation in a subset of melanomasLucia B Jilaveanu, Christopher R Zito, Saadia A Aziz, et al.
Journal for Immunotherapy of Cancer|March 24, 2017
Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanomaJames W Smithy, Lauren M Moore, Vasiliki Pelekanou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic SitesHarriet M Kluger, Christopher R Zito, Meaghan L Barr, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid TumorsChristian U Blank, Deborah J Wong, Thai H Ho, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2014
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivoRituparna Das, Rakesh Verma, Mario Sznol, et al.
Pageof 19